Staying Informed

Auven Therapeutics Announces AstraZeneca’s MedImmune Acquires Antibody-Drug Conjugate Company Spirogen and Invests in ...

LAUSANNE, Switzerland & LONDON & ST THOMAS, U.S. Virgin Islands & NEW YORK--(BUSINESS WIRE)--Auven Therapeutics today announced that its strategic investment in the ADC field has been validated by the sale of its platform technology portfolio Company Spirogen to AstraZeneca’s MedImmune.

 

This post is a mere snippet of world-wide industry news, sponsored by:
BizLocal.com
BizLocal is a web-property of Inspetta LLC, providing innovative web, software and marketing services to business.  Call 800-785-2925 for more information.

Comments
Only registered users can leave comments.
Comment text: